Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia

European Journal of Endocrinology

Volumn 143, Issue 4, 2000, Pages 543-554

  Ito, K ^a   Fukabori, Y ^a   Shibata, Y ^a   Suzuki, K ^a   Mieda, M ^a   Gotanda, K ^a   Honma, S ^a   Yamanaka, H ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7A MERCAPTO DEXTRO HOMO 17 OXA ANDROSTA 1,4 DIENE 3,17A DIONE; ANDROSTENEDIONE; AROMATASE; AROMATASE INHIBITOR; ATAMESTANE; CHLORMADINONE ACETATE; ESTRADIOL; LUTEINIZING HORMONE; TESTOSTERONE; TZA 2237; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; HORMONE BLOOD LEVEL; HORMONE INHIBITION; MALE; MUSCLE GROWTH; MUSCLE MASS; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SMOOTH MUSCLE;

EID: 0033777054     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1430543     Document Type: Article

References (48)

1. The development of human benign prostatic hyperplasia with age
2. Age related changes and interrelationships between plasma testosterone, oestradiol and testosterone-binding globulin in normal adult males
3. Effect of aging on endogenous level of 5α-dihydro-testosterone, testosterone, estradiol and estrone in epithelium and stroma of normal and hyperplastic human prostate
4. Hormonal changes and sexual function in aging men
5. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: Response to clomiphene citrate
6. The evidence of estrogen production in the prostate
7. Correlation among prostate stroma, plasma estrogen levels, and urinary estrogen excretion in patients with benign prostatic hypertrophy
8. Endocrine environment of benign prostate hyperplasia - Prostate size and volume are correlated with serum estrogen concentration
9. Changes in the endocrine environment of the human prostate transition zone with aging - Simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition
10. Androgen-regulated estrogen receptor β expression in human prostate
11. From estrogen to androgen receptor: A new pathway for sex hormone in prostate
12. Roles of estrogen and SHBG in prostate physiology
13. Estradiol causes rapid accumulation of c-AMP in human prostate
14. The Schering 90,062 Study Group. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostaic hyperplasia not requiring operation
15. The assay of progestine
16. Methods for monitoring canine prostate size: Internal and external caliper measurements
17. Level of LH, estradiol and progesterone in serum during the estrous cycle and pregnancy in the beagle bitch
18. Protein measurement with folin reagent
19. Steroid hormone receptors: Assay and characterization
20. A study of the conditions and mechanism of the diphenylamine reaction for the colorometric estimation deoxyribonucleic acid
21. Expression and degradation of rat androgen receptor following castration, testosterone replacement and antiandrogens administration: Analysis by Western blot and immunohistochemistry
22. Production of polyclonal antibody against human androgen receptor and immunohistochemical study of human androgen receptor in prostatic tissues
23. The effect of finasteride in men with benign prostatic hyperplasia
24. The effects of nafarelin acetate, a luteinizing hormone releasing hormone agonist, on benign prostatic hyperplasia
25. Effect of a GMRH analogue (Leuprolide) on benign prostatic hypertrophy
26. Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis
27. Light microscopic stereological analysis of the normal human prostate and benign prostatic hyperplasia
28. Morphometric evaluation of benign prostate hyperplasia
29. Quantitative topographic distribution of epithelial and mesenchymal components in benign prostatic hyperplasia
30. The effect of epidural anesthesia on the urethral closure pressure profile in patients with prostatic enlargement
31. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy
32. The induction of prostatic hypertrophy in the dog with androstanediol
33. Androgen and estrogen receptor content in spontaneous and experimentally induced canine prostatic hyperplasia
34. 5α-androstan-3α,17β-diol is a hormone: Stimulation of cAMP accumulation in human and dog prostate
35. A comparison of spontaneous and experimentally induced canine prostatic hyperplasia
36. Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: Preliminary results
37. Tissue distribution and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger ribonucleic acid in the wild-type and ERα-knockout mouse
38. Comparison of ligand binding specificity and transcript tissue distof estrogen receptors α and β
39. Effect of testosterone-estradiol administration on citric acid and fructose content of the rat prostate
40. Effect of prolactin on citric acid of lateral lobe of prostate of Sprague-Dawley rats
41. A difference in the in vitro accumulation and metabolism of testosterone-1,2-3H by the rat prostate gland following incubation with ovine or bovine prolactin
42. Prolactin effect on the permeability of benign hyperplastic prostate to testosterone
43. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies
44. Induction of estrogen-related hyperplastic changes in the prostate of the cynomolgus monkey (Macaca fascicularis) by androstenedione and its antagonization by the aromatase inhibitor 1-methylandrosta-1,4-diene-3,17-dione
45. Selective inhibition of androstenedione-induced prostate growth in intact beagle dogs by a combined treatment with the anti-androgen cyproterone acetate and the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione (1-methyl-ADD)
46. Effect of aromatase inhibitor, TZA-2209, in the prostate of androstenedione-treated castrated dogs: Changes in prostate volume and histopathological findings
47. Aromatase inhibition in the dog. I. Effect on serum LH, serum testosterone concentrations, testicular secretions and spermatogenesis
48. Effect of dual inhibition of 5-alpha-reductase and aromatase on spontaneously developed canine prostatic hypertrophy